Publication date: Jun 23, 2025
When compared to the TSPO-specific tracer ^1⁸F-D2-LW223, ^1⁸F-PDE-1905 demonstrated superior image quality and greater brain distribution, underscoring its promise for imaging neuroinflammation. Current clinical PET imaging for neuroinflammation primarily uses tracers that target TSPO, a downstream marker that is broadly expressed across multiple cell types. They then developed a mouse model of neuroinflammation and performed dynamic PET imaging using the ^1⁸F-PDE-1905 alongside the TSPO-specific tracer ^1⁸F-D2-LW223. PET imaging showed significantly higher uptake of ^1⁸F-PDE-1905 in the brains of diseased mice compared to controls, indicating increased tracer activity in neuroinflammatory conditions. “For patients, this could mean earlier and more accurate diagnoses, better tracking of treatment effectiveness, and more personalized therapies based on direct measures of neuroinflammation. Neuroinflammation-an immune response triggered by infection, toxin buildup, or injury in the central nervous system-is a key driver in the progression of many neurodegenerative and psychiatric disorders. “By directly targeting PDE4B, ^1⁸F-PDE-1905 provides a more specific and upstream view of microglial activation-an early and critical factor in the progression of many neurological diseases,” said Chen.
| Concepts | Keywords |
|---|---|
| Alzheimer | Brain |
| Annual | Developed |
| Bioinformatics | Diseases |
| Nervous | Imaging |
| Radiology | Immune |
| Multiple | |
| Neuroinflammation | |
| Pde | |
| Pde4b | |
| Pet | |
| Specific | |
| Tracer | |
| Treatment | |
| Tspo |
Semantics
| Type | Source | Name |
|---|---|---|
| disease | MESH | neurodegenerative disorders |
| drug | DRUGBANK | Tropicamide |
| disease | MESH | Parkinson’s disease |
| disease | MESH | brain inflammation |
| disease | MESH | multiple sclerosis |
| disease | MESH | Neuroinflammation |
| disease | MESH | infection |
| disease | MESH | psychiatric disorders |